Year-end report 2009

Year-end report 2009

GROUP FINANCIAL PERFORMANCE JANUARY - DECEMBER*) 
• Net sales were SEK 83.2 million  
• Operating income (EBIT) was SEK 18.7 million  
• Net income after tax amounted to SEK 10.2 million 
• Results of investing activities were  SEK 0.0 million 
• Earnings per share, basic and diluted, was SEK 0.69
• Equity per share was SEK 34.71
• Equity/assets ratio was 68 percent 

PARENT COMPANY FINANCIAL PERFORMANCE JANUARY - DECEMBER 
• Results of investing activities were (Group contributions) SEK 29.8 million
(0.0) 
• Other income was SEK 4.7 million (3.6) 
• Net income after tax was SEK 7.7 million (-13.9) 

KEY EVENTS IN THE FOURTH QUARTER
• Likvor receives first orders for CELDA™ from Norrland University Hospital and
Uppsala Univer-sity Hospital
• LinkMed acquires an additional 55.2 percent  of AbSorber, resulting in that
AbSorber becomes a new LinkMed subsidiary 
• LinkMed implements a guaranteed rights issue of convertibles worth SEK 84.9
million before issue costs
• AbSorber is granted patent in Europe for the XM-ONE®  transplantation test 
• Biovator enters into agreement with BASF

COMMENTS ON 2009 FROM LINKMED CEO INGEMAR LAGERLÖF:
“Operating income in 2009 was SEK 18.7 million despite non-recurring costs of
SEK 3.9 million in the second half of the year related to the transition to an
in-house sales organi-zation in the transplantation sector. Through the
acquisition of additional shares in Ab-Sorber, LinkMed now has an ownership
stake of 98 percent in the company and is thereby ultimately ready for a
combination with Olerup SPP to create a larger and more attractive
transplantation-sector company. The company strengthened its financial position
during the year through a rights issue consisting of shares and convertibles. In
addition, renegotiations and other measures reduced company commitments by a
total of SEK 50 million in 2009 and 2010, which also had a positive effect on
finances. LinkMed is therefore entering 2010 with a strong financial position
and robust cash flow from the company's transplantation sector operations. I am
looking forward to an eventful and exciting 2010, where several of our portfolio
companies can continue to take great strides forward, and where the value in our
companies gains even better visibility.” 

*) comparative figures for the Group are not reported as consolidated figures
are only available for the period July-December 2008.

For more information please contact:
Ingemar Lagerlöf, CEO, cell +46 70-873 2733 or email ingemar.lagerlof@linkmed.se

Okee Williams, Portfolio Manager, cell +46 70- 600 5364 or email
okee.williams@linkmed.se



LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management and capital, LinkMed has created a
portfolio of thirteen companies, four in drug development and biotechnology and
nine in diagnostics and medical technology. The company's principal shareholders
are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB.
LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section
(ticker: LMED).